Complete Response of an Iraqi Patient with Multiple Liver Metastasis, Colon Cancer and Deep Vein Thrombosis to XELOX/Bevacizumab Treatment

Rasha Mahroos Faris; Mohammed Mahmood Mohammed; Ayman Adnan Delan

doi:10.54133/ajms.v7i1(Special).922

Authors

Rasha Mahroos Faris Ramadi Maternity and Children Teaching Hospital, Anbar, Iraq https://orcid.org/0009-0002-8892-762X
Mohammed Mahmood Mohammed Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Ayman Adnan Delan Anbar Specialized Oncology Center, Anbar, Iraq

DOI:

https://doi.org/10.54133/ajms.v7i1(Special).922

Keywords:

Bevacizumab, Colon cancer, DVT, Metastasis , XELOX

Abstract

Background: The incidence of colon cancer is rising globally, and several therapeutic techniques, such as surgery, radiation, and systemic therapy, are used to control this illness. Patients with initially treatable metastatic colorectal cancer and unresectable metastases receive preoperative chemotherapy. In patients with rapidly progressing cancer, this strategy aims to shrink the tumor, manage any micro-metastases, and avoid liver surgery. Case presentation: We present a rare case of an Iraqi patient with metastatic colon cancer and an initially unresectable liver metastasis. The patient initially experienced a partial response to chemotherapy with capecitabine, oxaliplatin (XELOX), and Bevacizumab, but after a few days, we observed deep venous thrombosis (DVT). We stopped the oxaliplatin and administered Capecitabine with bevacizumab as a chemotherapy treatment, observing no adverse effects during the therapy period and achieving a complete response with Capecitabine and bevacizumab. Conclusions: The full response in the liver and colon after treatment, which reduced the patients' treatment burden, was the case's unique result. Additionally, this study highlights deep vein thrombosis as a critical problem that can arise with the use of oxaliplatin.

Downloads

Download data is not yet available.

References

Cancer. Who.int. 2021 [cited 31 August 2021]. Available at: https:// www.who.int/news-room/fact-sheets/detail/cancer

Vogel A, Hofheinz RD, Kubicka S, Arnold D. Treatment decisions in metastatic colorectal cancer - Beyond first- and second-line combination therapies. Cancer Treat Rev. 2017;59:54-60. doi: 10.1016/j.ctrv.2017.04.007.

Ibrahem S, Ahmed H, Zangana S. Trends in colorectal cancer in Iraq over two decades: incidence, mortality, topography and morphology. Ann Saudi Med. 2022;42(4):252-261. doi: 10.5144/0256-4947.2022.252.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019. doi: 10.1200/JCO.2007.14.9930.

Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for unresectable colorectal liver metastases. Ann Surg Oncol. 2001;8(4):347-353. doi: 10.1007/s10434-001-0347-3.

Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344-5351. doi: 10.1200/JCO.2008.17.5299.

Zhou P, Cao Y, Li M, Ma Y, Chen C, Gan X, et al. HCCANet: histopathological image grading of colorectal cancer using CNN based on multichannel fusion attention mechanism. Sci Rep. 2022;12(1):15103. doi: 10.1038/s41598-022-18879-1.

Adam R, Wicherts DA, de Haas RJ, Aloia T, Lévi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26(10):1635-1641. doi: 10.1200/JCO.2007.13.7471.

Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939-3945. doi: 10.1200/JCO.2006.05.8727.

Murayama M, Kohno T, Miyazawa M, Shimazaki A, Miyaki A, Usuda A, et al. A case of a recurrent hepatic metastasis occurred after curative resection of ascending colon cancer and a hepatic metastasis responding completely to capecitabine plus bevacizumab. Gan To Kagaku Ryoho. 2013;40(12):2014-2016. PMID: 24393997.

Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, et al. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Ann Oncol. 2017;28(9):2128-2134. doi: 10.1093/annonc/mdx322.

Garcia D, Momentary I, Fricke J, Schmolze D, Afkhami M, Mannan R, et al. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harb Mol Case Stud. 2023;9(2): a006262. doi: 10.1101/mcs. a006262.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249.

Ogata Y, Shimokawa M, Tanaka T, Emi Y, Oki E, Saeki H, et al. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol. 2016;21(2):335-343. doi: 10.1007/s10147-015-0895-3.

Haghpanah M, Azimi A, Fadavi P, Bagheri SM, Arefpour AM. The complete response of a renal cell carcinoma metastatic to brain, lungs, and liver to second-line nivolumab: A case report. Cureus. 2022;14(9):e29680. doi: 10.7759/cureus.29680.

Walko CM, Lindley C. Capecitabine: A review. Clin Ther. 2005;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005.

Comella P. A review of the role of capecitabine in the treatment of colorectal cancer. Ther Clin Risk Manag. 2007;3(3):421-431.

Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291-1305. doi: 10.1161/ATVBAHA.120.314378.

Rosati G, Avallone A, Aprile G, Butera A, Reggiardo G, Bilancia D. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013;71(1):257-264. doi: 10.1007/s00280-012-2004-x.

Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: A multicenter randomized trial. Lancet. 2003;361(9356):457-464. doi: 10.1016/s0140-6736(03)12461-0.